Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Status:
Completed
Trial end date:
2016-12-21
Target enrollment:
Participant gender:
Summary
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody
fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic
macular edema (DME), retinal vein occlusion and age-related macular degeneration.
Currently, there is limited epidemiologic information in Chile regarding the incidence of DME
and limited experience of anti-VEGF hospital therapy. This study will evaluate the efficacy
of intravitreal ranibizumab in Chilean DME patients, to investigate the anatomical and
functional improvement following this treatment and to increase the local experience
regarding the use of anti-VEGF in the treatment of diabetic macular edema.